אקסדרין Izrael - hebrejski - Ministry of Health

אקסדרין

gsk consumer healthcare, israel ltd - acetylsalicylic acid; caffeine; paracetamol - קפליות - paracetamol 250 mg; acetylsalicylic acid 250 mg; caffeine 65 mg - paracetamol, combinations excl. psycholeptics - paracetamol, combinations excl. psycholeptics - for temporary relief of the pain of headache, mild to moderate pain associated with migraine headache, pain of menstrual descomfort and pain accompanied by fever.

פוליקוטן Izrael - hebrejski - Ministry of Health

פוליקוטן

padagis israel pharmaceuticals ltd, israel - clotrimazole; dexamethasone acetate; neomycin sulfate - קרם - clotrimazole 1 %; neomycin sulfate 0.645 %; dexamethasone acetate 0.044 % - combinations - combinations - treatment of dermatitis involving also a bacterial and/or fungal infection.

אקמול צינון ליקוויג'ל ליום Izrael - hebrejski - Ministry of Health

אקמול צינון ליקוויג'ל ליום

teva israel ltd - paracetamol; pseudoephedrine as hydrochloride - קפסולות ממולאות נוזל - paracetamol 250 mg; pseudoephedrine as hydrochloride 30 mg - paracetamol

קוד-אקמול 15325 Izrael - hebrejski - Ministry of Health

קוד-אקמול 15325

teva israel ltd - codeine phosphate; paracetamol - טבליה - paracetamol 325 mg; codeine phosphate 15.0 mg - paracetamol, combinations excl. psycholeptics

אביטול  100 מג Izrael - hebrejski - Ministry of Health

אביטול 100 מג

teva pharmaceutical industries ltd, israel - tocopherol (vit e) (as tocopheryl acetate) - טבליה - tocopherol (vit e) (as tocopheryl acetate) 100 mg - tocopherol (vit e) - tocopherol (vit e) - for the prevention and treatment of diseases caused by vitamin e deficiency.

אביטול  200  מג Izrael - hebrejski - Ministry of Health

אביטול 200 מג

teva pharmaceutical industries ltd, israel - tocopherol (vit e) (as tocopheryl acetate) - טבליה - tocopherol (vit e) (as tocopheryl acetate) 200 mg - tocopherol (vit e) - tocopherol (vit e) - for the prevention and treatment of diseases caused by vitamin e deficiency.

אביטול  200  מג Izrael - hebrejski - Ministry of Health

אביטול 200 מג

teva pharmaceutical industries ltd, israel - tocopherol (vit e) (as tocopheryl acetate) - טבליה - tocopherol (vit e) (as tocopheryl acetate) 200 mg - tocopherol (vit e) - tocopherol (vit e) - for the prevention and treatment of diseases caused by vitamin e deficiency.

פראצטמול אלטן 10 מגמל Izrael - hebrejski - Ministry of Health

פראצטמול אלטן 10 מגמל

propharm ltd - paracetamol - תמיסה לאינפוזיה - paracetamol 10 mg / 1 ml - paracetamol

סיאנה Izrael - hebrejski - Ministry of Health

סיאנה

pfizer pfe pharmaceuticals israel ltd - medroxyprogesterone acetate - תרחיף להזרקה - medroxyprogesterone acetate 104 mg / 0.65 ml - medroxyprogesterone - medroxyprogesterone - * sayana is indicated for long-term female contraception. each subcutaneous injection prevents ovulation and provides contraception for at least 13 weeks (+/- 1 week). however, it should be taken into consideration that the return to fertility (ovulation) may be delayed for up to one year .since loss of bone mineral density may occur in females of all ages who use sayana long-term, a risk/benefit assessment, which also takes into consideration the decrease in bone mineral density that occurs during pregnancy and/or lactation, should be considered.* use in adolescents (12-18 years)in adolescents, use of sayana is only indicated when other contraceptive methods are considered unsuitable or unacceptable, due to unknown long-term effects of bone loss associated with sayana during the critical period of bone accretion.sayana has not been studied in women under the age of 18 years but data is available for intramuscular medroxyprogesterone acetate in this population.

קופקסון 20 מגמל Izrael - hebrejski - Ministry of Health

קופקסון 20 מגמל

teva israel ltd - glatiramer acetate - תמיסה להזרקה - glatiramer acetate 20 mg/ml - glatiramer acetate - glatiramer acetate - for reducing the frequency of relapses in pateints with relapsing-remitting multiple sclerosis. copaxone is indicated for the treatment of patients who have experienced a well defined first clinical episode and are determined to be at high risk of developing clinically definite multiple sclerosis (cdms). these patients should have mri findings which are compatible with the diagnosis of multiple sclerosis.